COMUNICADO: Janssen recibe la opinión positiva del CHMP sobre IMBRUVICA(TM) (y 3)

Actualizado 07/07/2015 23:30:34 CET

[TAB]
1) Reporte del Comité de Productos Médicos para Uso Humano (CHMP).
Disponible en
http://www.ema.europa.eu/docs/en_GB/document_library/Summary...
Visitado en julio de 2014.
2) McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and
management of mantle cell lymphoma. Br J Haematol. 2012;159:405-26.
3) Williams ME, Dreyling M, Winter J, Muneer S, Leonard JP. Management of mantle
cell lymphoma: key challenges and next steps. Clin Lymphoma Myeloma Leuk.
2010;10:336-46.
4) American Cancer Society. What is chronic lymphocytic leukemia? Disponible en:
http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/...
. Visitado por última vez en julio de 2014
5) Schnaiter A, Stilgenbauer S. 17p Deletion in chronic lymphocytic leukemia:
risk stratification and therapeutic approach. Hematol Oncol Clin N Am 2013;27:289-301.
6) Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK
inhibitors in clinical development. J Hematol Oncol 2013;6:59.
7) Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in
previously treated chronic lymphoid leukemia. N Engl J Med. 2014 May 31 [publicación
electrónica en anticipación a la impresa].
8) Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or
refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
9) Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of
B-cell differentiation. Nat Rev Immunol 2002;2:920-32.
10) Puri KD, di Paolo JD, Gold MR. B cell receptor signaling inhibitors for
treatment of autoimmune inflammatory diseases and B-cell malignancies. Int Rev Immunol
2013;32:397-427.
11) Kil LP, de Bruiin MJ, van Nimwegen M, et al. Btk levels set the threshold
for B-cell activation and negative selection of autoreactive B cells in mice. Blood
2012;119:3744-56.
12) Sukbuntherng J, Jejurkar P, Chan S, et al. Pharmacokinetics (PK) of
ibrutinib in patients with chronic lymphocytic leukemia (CLL). J Clin Oncol
2013;31(Suppl.):abstract 7056.
13) Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines
Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl.6):vi50-4.
14) Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies
in Europe by morphologic subtype: results of the HAEMACARE project. Blood
2010;116:3724-34.
15) Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in
chronic lymphocytic leukemia. Cancer Control 2012;19:18-25.
16) Sellner L, Denzinger S, Dietrich S, et al. What Do We Do with Chronic
Lymphocytic Leukemia with 17p Deletion? Curr Hematol Malig Rep 2013;8:81-90
17) Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival
in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
18) Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and
other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011;21:293-8.
19) Leukemia and Lymphoma Society. Mantle cell lymphoma facts. Disponible en:
http://www.lls.org/content/nationalcontent/resourcecenter/fr...
Visitado por última vez en el 14 de mayo de 2013.
20) Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or
refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter
phase 2 PINNACLE study. Ann Oncol 2009:20:520-5.
[FTAB]

[TAB]

Video:
http://www.multivu.com/mnr/71400594-janssen-CHMP-opinion-tre...

[FTAB]

CONTACTO: Consultas de medios: Satu Kaarina Glawe. Móvil:+49-(172)-294-6264 E-mail: sglawe@its.jnj.com Relaciones con inversores:Stan Panasewicz. Tel: +1-732-524-2524 Louise Mehrotra Tel.: +1-732-524-6491

Europa Press Comunicados Empresas